{
  "name" : "dacemirror.sci-hub.se_journal-article_2e8193093beeb076af145547daae95a8_demelo-diogo2019.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : null,
    "authors" : [ ],
    "emails" : [ "demelodiogo@fcsaude.ubi.pt,", "icorreia@ubi.pt" ],
    "sections" : [ {
      "heading" : null,
      "text" : "Biomaterials Science\nREVIEW\nCite this: DOI: 10.1039/c9bm00577c\nReceived 10th April 2019, Accepted 22nd June 2019\nDOI: 10.1039/c9bm00577c\nrsc.li/biomaterials-science\nGraphene family nanomaterials for application in cancer combination photothermal therapy\nDuarte de Melo-Diogo, *†a Rita Lima-Sousa, †a Cátia G. Alves †a and Ilídio J. Correia *a,b\nCombining hyperthermia with other therapies holds a great potential for improving cancer treatment. In\nthis approach, the increase in the body temperature can exert a therapeutic effect on cells and/or\nenhance the effectiveness of anticancer agents. However, the conventional methodologies available to\ninduce hyperthermia cannot confine a high temperature increase to the tumor-site while maintaining\nhealthy tissues unexposed and ensuring minimal invasiveness. To overcome these limitations, combi-\nnation photothermal therapy (PTT) mediated by graphene family nanomaterials (GFN) has been showing\npromising results. Such is owed to the ability of GFN to accumulate at the tumor site and convert near\ninfrared light into heat, enabling a hyperthermia with a high spatial-temporal resolution. Furthermore,\nGFN can also incorporate different therapeutic agents on their structure for delivery purposes to cancer\ncells. In this way, the combination PTT mediated by GFN can result in an improved therapeutic effect. In\nthis review, the combination of GFN mediated PTT with chemo-, photodynamic-, gene-, radio-, and\nimmuno-therapies is examined. Furthermore, the main parameters that influence these types of combi-\nnation approaches are also analyzed, with emphasis on the photothermal potential of GFN and on the\nvascular and cellular effects produced by the temperature increase mediated by GFN."
    }, {
      "heading" : "1. Introduction",
      "text" : "Combining hyperthermia with radio- or chemo-therapies is a promising approach to improve cancer treatment.1,2 In these therapeutic modalities, the increase in the body temperature (hyperthermia) can exert a therapeutic effect on cells and/or enhance the effectiveness of the other anticancer agents. In this way, the outcome of hyperthermia-based combination\nDuarte de Melo-Diogo\nDuarte de Melo-Diogo received his B.Sc. and M.Sc. degrees in Biomedical Sciences from Universidade da Beira Interior in 2012 and 2014, respectively. In 2018, Duarte de Melo-Diogo concluded his Ph.D. degree in Biochemistry from the same university. He is now a researcher at CICS-UBI research center. His research interests are focused on the biomedical application of graphene family nanomaterials and on the development of functional nanostructures for cancer therapy.\nRita Lima-Sousa\nRita Lima-Sousa received her B.Sc. in Biochemistry and M.Sc. in Biomedical Sciences from the Universidade da Beira Interior in 2016 and 2018, respectively. Currently, Rita Lima-Sousa is a Ph.D. student in Biochemistry at the same university. Her research interests are focused in the development and functionalization of graphene family nanomaterials for application in cancer photothermal therapy and biomedicine.\n†These authors contributed equally to this article.\naCICS-UBI – Centro de Investigação em Ciências da Saúde, Universidade da Beira Interior, 6200-506 Covilhã, Portugal. E-mail: demelodiogo@fcsaude.ubi.pt, icorreia@ubi.pt bCIEPQPF – Departamento de Engenharia Química, Universidade de Coimbra, Rua Sílvio Lima, 3030-790 Coimbra, Portugal\nThis journal is © The Royal Society of Chemistry 2019 Biomater. Sci.\nPu bl\nis he\nd on\n2 4\nJu ne\n2 01\n9. D\now nl\noa de\nd by\nK E\nA N\nU N\nIV E\nR SI\nT Y\no n\n7/ 18\n/2 01\n9 8:\n23 :3\n5 A\nM .\nView Article Online View Journal\ntherapies is highly dependent on the maximum temperature achieved. However, the methodologies available to induce hyperthermia can limit its full therapeutic potential since these do not confine a high temperature increase to the tumor-site while maintaining healthy tissues unexposed and ensuring a minimal procedure invasiveness.3,4\nTo overcome these limitations, combination photothermal therapy (PTT) mediated by nanomaterials is a promising approach.1,5–9 This type of therapy employs precisely engineered nanostructures that, due to their physicochemical properties, can achieve a high tumor accumulation.10–13 Subsequently, the tumor zone is irradiated with laser light, and the nanomaterials’ accumulated in this site interact with this radiation, producing an on-demand temperature increase.12,14,15 The use of near infrared (750–1000 nm; NIR) light in these procedures is fundamental since it has minimal or insignificant interactions with biological components (e.g. water, collagen, melanin), thus ensuring a high penetration depth and minimal off-target heating.5,12,16,17 Furthermore, these NIR-responsive nanomaterials may also accommodate other anticancer agents on their structure,18–25 enabling the pursuit of synergistic therapeutic outcomes.\nAmong the different types of materials capable of being efficiently applied in combination PTT, graphene family nanomaterials (GFN) have been showing very promising results.26–32 Such is owed to the GFN ability to absorb NIR light and convert it into heat, enabling a PTT with a high spatial-temporal resolution.33–37 Furthermore, the aromatic lattice of GFN enables the direct loading of different agents (e.g. drugs, photosensitizers) on their structure for delivery purposes to cancer cells.38–41 In this way, combining the photothermal and delivery capacities of GFN can result in an improved therapeutic effect.\nIn this review, the cancer combination PTT mediated by GFN is analyzed. Firstly, the synthesis and general properties of GFN are overviewed (section 2). Afterwards, the main parameters that influence the combination PTT mediated by GFN are reviewed (section 3), with emphasis on the photothermal\npotential of GFN (section 3.1), and on the vascular and cellular effects produced by the temperature increase mediated by GFN (section 3.2). Then, the combination of GFN mediated PTT with chemotherapy (section 4), photodynamic therapy (section 5), gene therapy (section 6), radiotherapy (section 7), and immunotherapy (section 8) is reviewed. Finally, an outlook about the state of the art and the future directions are presented in section 9. For the sake of simplicity, this review will not cover the application of GFN mediated PTT in conjugation with other photothermal agents (e.g. gold nanorodsGFN hybrids) nor with porous nanostructures with loading capacity (e.g. mesoporous silica-GFN hybrids)."
    }, {
      "heading" : "2. GFN: synthesis and general properties",
      "text" : "The members of the GFN are synthesized through different routes (extensively reviewed in ref. 42–44), originating materials with distinct properties that influence their application in cancer therapy.\nGraphene oxide (GO) is commonly explored in photothermal applications and is also used as a precursor for the preparation of other GFN.32 This nanomaterial is composed of a monolayer graphitic lattice incorporating several types of oxygen functional groups such as hydroxyl, carboxyl or epoxy (Fig. 1). The chemical oxidation of graphite and exfoliation of the attained material is the process usually employed to produce GO.45,46 In this regard, the improved Hummers’ method (uses H2SO4, H3PO4 and KMnO4 for graphite oxidation) has been widely used to produce GO due to its high reaction yield.46 The NIR absorption of GO allows its application in photothermal therapy (discussed in detail in section 3.1.). Furthermore, the aromatic lattice of this nanomaterial enables the direct loading of different therapeutic agents on its structure through hydrophobic–hydrophobic interactions and/or π–π stacking.38,47–49\nGO can also be treated with reducing agents (e.g. hydrazine hydrate,34,50 L-ascorbic acid,51 glucose52) at 80–95 °C, yielding\nCátia G. Alves\nCátia G. Alves received her B.Sc. and M.Sc. degrees in Biomedical Sciences from Universidade da Beira Interior in 2016 and 2018, respectively. She is now a Ph.D. student in Biomedicine at the same university. Her research interests are focused on the application of NIR light responsive nanomaterials and small molecules in cancer theragnostic.\nIlídio J. Correia\nIlídio J. Correia is an Associate Professor with habilitation in the Department of Health Sciences at Universidade da Beira Interior. He obtained his B.Sc. and Ph.D. degrees in Biochemistry from University of Lisbon in 1998 and New University of Lisbon in 2003, respectively. His research group is involved in the development of skin and bone substitutes, drug delivery systems, as well as in vitro 3D cell culture models aimed to reproduce solid tumors structural features.\nBiomater. Sci. This journal is © The Royal Society of Chemistry 2019\nPu bl\nis he\nd on\n2 4\nJu ne\n2 01\n9. D\now nl\noa de\nd by\nK E\nA N\nU N\nIV E\nR SI\nT Y\no n\n7/ 18\n/2 01\n9 8:\n23 :3\n5 A\nM .\nreduced graphene oxide (rGO) (Fig. 1). This treatment intents to restore the graphitic aromatic lattice by removing the oxygen-functional groups, resulting in an improvement in the nanomaterials’ NIR absorption.32,34 When compared to GO, rGO also presents a higher drug loading capacity,53,54 thereby being a promising agent for the delivery of therapeutics to cancer cells.\nThere are other GFN with a good photothermal potential but whose application in cancer therapy is not so widespread since their synthesis is more complex. This group includes graphene oxide nanoribbons (GONR), reduced graphene oxide\nnanoribbons (rGONR) and reduced graphene oxide nanomesh (rGONM).\nGONR are produced through the oxidation of multiwall carbon nanotubes (using KMnO4 and H2SO4).\n55,56 This process also leads to the unzipping of the nanotubes (Fig. 1).55,56 The chemical treatment of GONR with reducing agents (e.g. hydrazine hydrate) generates rGONR, which also display an enhanced NIR absorption.55\nrGONM is produced through the photodegradation of GO (using TiO2 nanoparticles immobilized on a SiO2-film and radiation from a mercury lamp) and subsequent reduction\nFig. 1 Synthesis routes of the members of the GFN.\nThis journal is © The Royal Society of Chemistry 2019 Biomater. Sci.\nPu bl\nis he\nd on\n2 4\nJu ne\n2 01\n9. D\now nl\noa de\nd by\nK E\nA N\nU N\nIV E\nR SI\nT Y\no n\n7/ 18\n/2 01\n9 8:\n23 :3\n5 A\nM .\n(using hydrazine hydrate) of the attained material (Fig. 1).57 The use of rGONM for cancer PTT is also appealing due to its improved NIR absorption.57\nNevertheless, the as-synthesized GFN present critical limitations that hinder their direct application in cancer therapy. Even though GO based materials have some water solubility (due to their oxygen-functional groups), these materials precipitate in saline solutions and biological fluids.32,34 Several reports have shown that as-synthesized GO based materials can present a cytocompatible profile in vitro (which is dependent on multiple factors, such as materials’ physicochemical properties, impurities, presence of serum).32 However, the in vivo intravenous administration of GO leads to its accumulation and retention in the lungs, inducing severe effects on this organ.58 The rGO derivatives display limited water solubility and also precipitate in biological-relevant media.32,34 Furthermore, rGO derivatives are highly cytotoxic, a fact that can be attributed to their insolubility and contamination with traces of hydrazine hydrate (a highly toxic reducing agent used in the majority of the protocols followed to produce rGO derivatives).32,52\nThe limitations of as-synthesized GFN can be surpassed by functionalizing them with materials (e.g. hydrophilic polymers) capable of enhancing nanostructures’ colloidal stability and biocompatibility (extensively reviewed by our group in ref. 32). In this way, the functionalization of GFN enables their application in cancer therapy.32 For this purpose, the carboxyl groups of GO based materials can be covalently bond to primary amine-terminated polymers using the carbodiimide chemistry.32,34,59 In this regard, Yang et al. demonstrated that GO derivatives functionalized with amine-terminated branched poly(ethylene glycol) (PEG) did not induce any toxicity to mice when administered by intravenous, intraperitoneal and oral routes, thus displaying an excellent biocompatibility in vivo.59,60 Similar findings were also observed for GO functionalized with amine-terminated Dextran.61 On the other hand, the aromatic lattice of the rGO based materials can be functionalized with amphiphilic polymers through hydrophobic-hydrophobic interactions and/or π–π stacking.32,34,51,55,57 In this regard, rGO functionalized with PEGylated poly(maleic anhydride-alt-1-octadecene) and bovine serum albumin also displayed a biocompatibility profile suitable for in vivo applications.60,62,63"
    }, {
      "heading" : "3. GFN mediated combination PTT",
      "text" : "The application of GFN in cancer combination PTT generally starts with the administration of these nanomaterials through intravenous injection.62,64–66 After entering into the blood circulation, GFN can accumulate in the tumor zone by taking advantage from the tumor’s leaky vasculature (enhanced permeability and retention (EPR) effect) and from the dynamic vents that spontaneously occur in the tumor associated vessels.32,67,68 Subsequently, the tumor zone is exposed to NIR light and the GFN convert the absorbed radiation into\nheat.32,34 In this way, GFN can confine the hyperthermia to this site and elicit minimal off-target heating.12,32 The attained temperature increase in the tumor zone can per se induce damage on cancer cells and/or sensitize them to the action of other agents, leading to an improved therapeutic outcome.\nIn this way, the combination PTT mediated by GFN depends strongly on three factors: (i) the ability of GFN to reach the tumor zone, (ii) the intrinsic photothermal capacity of each member of the GFN and (iii) the temperature variation achieved, upon laser irradiation, at the tumor site.\nThe ability of GFN to effectively reach the tumor zone is dependent on the nanostructures’ physicochemical properties, namely on their size, charge, corona composition and decoration with targeting ligands.32 These properties and considerations regarding GFN biodistribution were recently analyzed by our group and by other research teams (reviewed in detail in ref. 32 and 69–71). In turn, the photothermal capacity of GFN is influenced by the NIR absorption of each derivative (reviewed in section 3.1), while the therapeutic outcome of the combination PTT is affected by the local temperature variation achieved upon irradiation (reviewed in section 3.2)."
    }, {
      "heading" : "3.1. Photothermal capacity of GFN",
      "text" : "The members of GFN have different capabilities to absorb the NIR radiation, ultimately impacting their photothermal capacity and hence their potential for combination PTT.\nDue to its NIR absorption, GO can produce a temperature increase upon interaction with NIR light. The attained temperature variation is dependent on the concentration of GO and on the laser related parameters (e.g. intensity, duration).23,72\nThe reduction of GO restores the nanostructures’ aromatic lattice, thus improving their NIR absorption and photothermal potential.32,34 In this regard, Yang et al. demonstrated that rGO based materials can display a 3–4 fold higher NIR absorption than GO derivatives.34 Consequently, the GO derivatives could produce a temperature increase to about 44 °C under NIR laser irradiation, while the rGO based materials induced a photoinduced heat to ≈58 °C (808 nm, 1 W cm−2, 5 min).34 However, the manipulation of rGO based materials is not straightforward. The rGO derivatives can aggregate irreversibly during the reduction phase, thus requiring additional processing steps.34,50 Furthermore, the use of rGO demands additional purification routines to ensure the removal of the reducing agents, some of which are cytotoxic.34,73 Due to these reasons, GO derivatives are still widely explored in cancer PTT.\nThe other GFN can display an enhanced photothermal capacity. GONR present a NIR absorption similar to that of GO based materials.55 In contrast, rGONR based materials can display a ≈2.4-fold higher absorption at 808 nm than rGO derivatives.55 Such phenomenon was attributed to the higher abundance of low-energy vibrational modes in rGONR arising from their intrinsic shape.55 Due to their higher NIR absorption, the rGONR based materials could produce a temperature increase up to ≈61 °C under NIR laser irradiation, while the rGO derivatives only raised the temperature to ≈46 °C (808 nm, 7.5 W cm−2, 10 min).55\nBiomater. Sci. This journal is © The Royal Society of Chemistry 2019\nPu bl\nis he\nd on\n2 4\nJu ne\n2 01\n9. D\now nl\noa de\nd by\nK E\nA N\nU N\nIV E\nR SI\nT Y\no n\n7/ 18\n/2 01\n9 8:\n23 :3\n5 A\nM .\nAkhavan et al. demonstrated that rGONM displays a 4.2-fold higher NIR absorption than rGO based materials.57 A greater restoration of rGONM aromatic lattice and/or a higher abundance of low-energy vibrational modes in this nanomaterial can explain its enhanced NIR absorption.55,57 Due to this fact, rGONM can produce a photoinduced heat to ≈57 °C (808 nm, 0.1 W cm−2, 8 min).57 Under the same conditions, the rGO based materials only produced a temperature increase to about 42 °C.57"
    }, {
      "heading" : "3.2. Effect of the temperature increase mediated by GFN",
      "text" : "The local temperature increase mediated by GFN upon NIR laser irradiation will dictate the therapeutic outcome of the combination PTT. Depending on the temperature achieved, the photoinduced heat mediated by GFN can induce irreversible or reversible damage on cells. In this context, achieving a\nphotoinduced heat to about 50 °C can per se induce irreversible damage on cells, causing protein denaturation, collapse of cells’ membrane, and dysfunctions on the activity of enzymes and mitochondria.74 These events ultimately lead to cells’ death by coagulative necrosis.74\nOn the other hand, a local temperature increase to about 41–45 °C can per se induce sub-lethal and reversible damage on cells by compromising cells’ metabolism and DNA repair mechanisms.74,75 Furthermore, this temperature range can also sensitize cells to the action of other therapeutics or enhance therapeutics’ efficacy, leading to an improved outcome.75\nMild hyperthermia can increase the blood flow into the tumor tissue, improving tissues’ oxygenation.75,76 Moreover, this increased blood flow can also augment the amount of GFN that reach the tumor zone (hyperthermia enhanced EPR\nFig. 2 Illustration of the vascular and cellular effects of GFN mediated photoinduced heat.\nThis journal is © The Royal Society of Chemistry 2019 Biomater. Sci.\nPu bl\nis he\nd on\n2 4\nJu ne\n2 01\n9. D\now nl\noa de\nd by\nK E\nA N\nU N\nIV E\nR SI\nT Y\no n\n7/ 18\n/2 01\n9 8:\n23 :3\n5 A\nM .\nT ab\nle 1\nC o m b in at io n P T T m e d ia te d b y G FN\n: in\nvi vo\nre su\nlt s\nG FN\nM od\nal it y\nTu m or\nm od\nel A dm\nin is tr at io n\nro ut e\nD os e\nLa se r pa ra m et er s\nTu m or te m pe\nra tu re\no\nO ut co m e of co m bi n at io n th er ap\ny O ut co m e of\nst an\ndal on e th er ap ie s\nR ef .\nD O X lo ad ed la ct of er ri n /r G O ba se d n an oc ap\nsu le s\nC h em\noPT\nT R G 2 tu m or be ar in g m ic e\ni.v .a\nD O X lo ad ed la ct of er ri n /r G O ba se d n an oc ap\nsu le s:\n25 m g kg\n− 1\n80 8 n m ,2 W cm − 2 ,5 m in\n55 °C\n(8 08\nn m ,\n2 W\ncm − 2 ,\n3 m in )\nTu m or er ad\nic at io n\nLa ct of er ri n /r G O ba\nse d\nn an\noc ap\nsu le s + N IR :\ntu m or\ngr ow\nth re du\nct io n\n83\nD O X :1\n.2 8 m g kg\n− 1\nFr ee\nD O X :t um or gr ow th re du ct io n\nE PI\nb lo ad ed C et ux im ab\n-P E G -G O\nC h em\noPT\nT U 87\ntu m or be ar in g m ic e\ni.v .\nE PI\nlo ad ed C et ux im ab\n-P E G -G O :\n6 m g kg\n− 1\n80 8 n m ,2 W cm − 2 ,2 m in\n88 °C\nTu m or er ad\nic at io n\nE PI\nlo ad\ned C et ux\nim ab - PE G -G O :t um or gr ow th re du ct io n\n64\nE PI :3\nm g kg\n− 1\nE PI\nlo ad\ned PE\nG -G O :\ntu m or\ngr ow\nth re du\nct io n\nC et ux\nim ab\n:0 .2\nm g\nkg − 1\nFr ee\nE PI :t um\nor gr ow th re du ct io n\nPl at in um\n-P E G -G O\nco m pl ex\nC h em\noPT\nT 4T\n1 tu m or be ar in g m ic e\ni.v .\nPl at in um\n:1 0 m g\nkg − 1 (t w ic e)\n78 5 n m ,1\n.5 W\ncm − 2 ,3\nm in\n(t w ic e)\nN .A .\nTu m or er ad\nic at io n\nPE G -G O + N IR :t um or gr ow th in h ib it io n .\n77\nPl at in um\n-P E G -G O\nco m pl ex :t um\nor gr ow th re du ct io n C is pl at in :t um or gr ow th re du ct io n\nR V c lo ad\ned m PE\nG d /\nrG O\nC h em\noPT\nT 4T\n1 tu m or be ar in g m ic e\ni.t .e\nG O :1\n0 m g kg\n− 1\n80 8 n m ,0\n.6 W\ncm − 2 ,5\nm in\n70 °C\nTu m or er ad\nic at io n\nm PE\nG /r G O + N IR :\ntu m or\ngr ow\nth re du\nct io n\n54\nR V :1\n8 m g kg\n− 1\nFr ee\nR V :t um\nor gr ow th re du ct io n\nD O X lo ad ed m PE G -G O\nC h em\noPT\nT E M T 6 tu m or be ar in g m ic e\ni.v .\nD O X :1\n0 m g kg\n− 1\n80 8 n m ,2 W cm − 2 ,5 m in\n50 °C\n(i .t .)\nTu m or er ad\nic at io n (i n\n4 ou\nt of\n5 m ic e)\nm PE\nG -G O + N IR :t um or gr ow th re du ct io n\n95\nFr ee\nD O X :t um or gr ow th re du ct io n\nM IT\nf lo ad\ned H A g -\nG O\nC h em\noPT\nT M C F7 tu m or be ar in g m ic e\ni.v .\nM IT :4\nm g kg\n− 1\n(e ve ry\n2 da\nys fo r 7\nda ys )\n80 8 n m ,2 W cm − 2 ,1 m in (e ve ry 2 da\nys fo r\n7 da\nys )\nN .A .\nTu m or re gr es si on\nH A -G O + N IR :t um or gr ow th re du ct io n\n65\nFr ee\nM IT\n+ N IR :t um or gr ow th in h ib it io n\nD SP\nE -P E G h -N G R i /\nD O X -G O @ A g n an oc om\npo si te\nC h em\noPT\nT S1\n80 tu m or be ar in g m ic e\ni.v .\nD SP\nE -P E G -N G R /\nG O @ A g:\n6. 1 m g kg\n− 1\n80 8 n m ,2 W cm − 2 ,3 m in (e ve ry 2 da\nys )\nN .A .\nTu m or re gr es si on\nD SP\nE -P E G -N G R /G O @ A g\n+ N IR :t um\nor gr ow th re du ct io n\n85\nD O X :5\nm g kg\n− 1\n(e ve ry\n2 da\nys )\nD SP\nE -P E G -N G R / D O X -G O @ A g:\ntu m or\ngr ow\nth re du\nct io n\nFr ee\nD O X :t um or gr ow th re du ct io n\nR V lo ad\ned PE\nG D E j /\nG O\nC h em\noPT\nT 4T\n1 tu m or be ar in g m ic e\ni.t .\nG O :1\n0 m g kg\n− 1\n80 8 n m ,0\n.6 W\ncm − 2 ,5\nm in\n47 °C\nTu m or\ngr ow th re du ct io n\nPE G D E /G O + N IR : tu m or gr ow th re du\nct io n\n54\nR V :1\n8 m g kg\n− 1\nFr ee\nR V :t um\nor gr ow th re du ct io n\nBiomater. Sci. This journal is © The Royal Society of Chemistry 2019\nPu bl\nis he\nd on\n2 4\nJu ne\n2 01\n9. D\now nl\noa de\nd by\nK E\nA N\nU N\nIV E\nR SI\nT Y\no n\n7/ 18\n/2 01\n9 8:\n23 :3\n5 A\nM .\nT ab\nle 1\n(C o n td .)\nG FN\nM od\nal it y\nTu m or\nm od\nel A dm\nin is tr at io n\nro ut e\nD os e\nLa se r pa ra m et er s\nTu m or te m pe\nra tu re\no\nO ut co m e of co m bi n at io n th er ap\ny O ut co m e of\nst an\ndal on e th er ap ie s\nR ef .\nD O X lo ad ed H A -S SG O\nC h em\noPT\nT M D A -M\nB -2 31\ntu m or\nbe ar in g\nm ic e\ni.v .\nD O X :5\nm g kg\n− 1\n(e ve ry\n3 da\nys fo r 18\nda ys )\n80 8 n m ,5 W cm − 2 ,1\n0 m in\n(e ve ry\n3 da\nys fo r\n18 da\nys )\nN .A .\nTu m or\ngr ow th re du ct io n\nH A -S SG O + N IR :t um or gr ow th re du ct io n\n84\nD O X lo ad\ned H A -S SG O :\ntu m or\ngr ow\nth re du\nct io n\nFr ee\nD O X :t um or gr ow th re du ct io n\nM et h yl en\ne bl ue\nlo ad\ned Pl ur on ic F1 27 /G O\nPh ot od\nyn am\nic -\nPT T\n4T 1- Lu\nc tu m or\nbe ar in g m ic e\ni.t .\nPl ur on\nic F1\n27 /G O :\n10 m g kg\n− 1\n66 0 n m ,9\n0. 8 J\ncm − 2 ,1\n0 m in\n70 °C\n(8 08\nn m ,\n8. 3 kJ\ncm − 2 ,\n3 m in )\nTu m or er ad\nic at io n\nM et h yl en\ne bl ue\nlo ad ed Pl ur on ic F1 27 /G O + N IR :t um or gr ow th re du ct io n\n89\nM et h yl en\ne bl ue : 2. 5 m g kg − 1 (3\nti m es )\n80 8 n m ,8\n.3 kJ\ncm − 2 ,1\n5 m in\n(3 ti m es )\nM et h yl en\ne bl ue\nlo ad ed Pl ur on ic F1 27 /G O + 66 0 n m :t um or gr ow th re du ct io n\nIR 80\n8- bP\nE Ik -\nPE G -G O\nPh ot od\nyn am\nic -\nPT T\nA 54\n9 tu m or be ar in g m ic e\ni.v .\nIR 80\n8- bP\nE IPE\nG -G O :\n10 m g kg\n− 1\n80 8 n m ,1 W cm − 2 ,5 m in\n59 °C\nTu m or er ad\nic at io n\nbP E IPE\nG -G O + N IR :\ntu m or\ngr ow\nth re du\nct io n\n66\nbP E IPE\nG -G O :8\nm g\nkg − 1\nFr ee\nIR 80\n8 + N IR :\ntu m or\ngr ow\nth re du\nct io n\nIR 80\n8: 2 m g kg\n− 1\nM et h yl en\ne bl ue\nlo ad\ned Pl ur on ic F1 27 /G O\nPh ot od\nyn am\nic -\nPT T\nH eL\na tu m or be ar in g m ic e\ni.v .\nPl ur on\nic F1\n27 /G O :\n10 m g kg\n− 1\n65 0 n m , ≈ 15 0 m W cm − 2 ,1\n0 m in\n50 °C\nTu m or er ad\nic at io n\nM et h yl en\ne bl ue\nlo ad ed Pl ur on ic F1 27 /G O + N IR :t um or gr ow th re du ct io n\n87\nM et h yl en\ne bl ue : 2 m g kg − 1\n80 8 n m ,2 W cm − 2 ,3 m in\nM et h yl en\ne bl ue\nlo ad ed Pl ur on ic F1 27 /G O + 65 0 n m :t um or gr ow th re du ct io n\nPE G -R u(\nII )c\nom pl ex\nlo ad\ned rG\nO Ph\not od\nyn am\nic -\nPT T\nA 54\n9 tu m or be ar in g m ic e\ni.t .\nPE G -R u(\nII ) co m pl ex\nlo ad\ned rG\nO :5\nµg g−\n1 80\n8 n m ,0\n.5 W\ncm − 2 ,5\nm in\n59 °C\nTu m or re gr es si on\nPE G -R u(\nII )c\nom pl ex\nlo ad\ned rG\nO + N IR :\ntu m or\ngr ow\nth re du\nct io n\n88\n45 0 n m ,2\n0 m W\ncm − 2 ,2\nm in\nPE G -R u(\nII )c\nom pl ex\nlo ad\ned rG\nO + 45\n0 n m :\ntu m or\ngr ow\nth re du\nct io n\nH D AC\n1 an\nd K -R as si R N A co m pl ex ed PA H /f ol ic ac id - PE G -G O\nG en\nePT\nT M IA\nPa C a2\ntu m or\nbe ar in g\nm ic e\ni.p .l\nPA H /f ol ic\nac id -\nPE G -G O :4\nm g kg\n− 1\n80 8 n m ,1 W cm − 2 ,1 m in (o n ce ev er y 4 da ys )\nN .A .\nTu m or\ngr ow th re du ct io n\nPA H /f ol ic\nac id -P E G -G O\n+ N IR :t um\nor gr ow th re du ct io n\n90\nH D AC\n1 si R N A :1\n6 µg\nH D AC\n1 an\nd K -R as si R N A co m pl ex ed\nPA H /\nfo li c ac id -P E G -G O : tu m or gr ow th re du\nct io n\nK -R as\nsi R N A :1\n6 µg\n(o n ce\nev er y 4 da\nys )\n1 3 1 I la be\nle d\nC 1 8 PM\nH m -P E G /r G O\nR ad\nio -P T T\n4T 1 tu m or be ar in g m ic e\ni.v .\n1 3 1 I la be\nle d\nC 1 8 PM\nH -P E G /r G O :\n10 m g kg\n− 1\n80 8 n m ,0\n.2 W\ncm − 2 ,2\n0 m in\n45 –4\n6 °C\nTu m or er ad\nic at io n (i n\n4 ou\nt of\n5 m ic e)\n1 3 1 I la be\nle d\nC 1 8 PM\nH -P E G /r G O :\ntu m or\ngr ow\nth re du\nct io n\n62\n1 3 1 I: 20\n0 µC\ni 1 3 1 I: tu m or\ngr ow th re du ct io n\nThis journal is © The Royal Society of Chemistry 2019 Biomater. Sci.\nPu bl\nis he\nd on\n2 4\nJu ne\n2 01\n9. D\now nl\noa de\nd by\nK E\nA N\nU N\nIV E\nR SI\nT Y\no n\n7/ 18\n/2 01\n9 8:\n23 :3\n5 A\nM .\neffect).77 As a result of the mild hyperthermia, cells’ membrane permeability is also affected.75,78 In this way, the temperature increase produced by GFN upon NIR laser irradiation can improve nanomaterials’ cellular uptake.40,72,79 The photoinduced heat generated by GFN can also disrupt the endosomes/lysosomes, prompting the delivery of the loaded agents to the cytoplasm.53,80 Additionally, the interaction of the GFN with NIR light can trigger the intracellular release of the loaded therapeutics.54 By taking advantage from these mechanisms (illustrated in Fig. 2) and from the effects of the hyperthermia per se, GFN mediated PTT can improve the therapeutic outcome of different types of therapies (reviewed in the following sections)."
    }, {
      "heading" : "4. PTT mediated by GFN in combination with chemotherapy",
      "text" : "The aromatic lattice of GFN allows the direct loading of chemotherapeutics on their structure through hydrophobic–hydrophobic interactions and/or π–π stacking.81,82 In this way, GFN can be explored to control the delivery of drugs to cancer cells. Chen et al. demonstrated that the NIR light can trigger the release of resveratrol from rGO based materials inside cancer cells.54 By exposing cells to NIR light for 10 min, the intracellular release of this drug increased from about 3% to ≈30%.54 Such behavior can be attributed to the detachment of the drugs from GFN due to the local temperature increase achieved upon NIR laser irradiation.54,83 Additionally, the photoinduced heat generated by both GO and rGO based materials can also disrupt the endo/lysosomes,53,84 further contributing to the release of the loaded drugs in the cytoplasm.\nBy taking advantage from these two phenomena and from the cellular effects of the hyperthermia per se, GFN mediated chemo-PTT can lead to improved therapeutic outcomes (Tables 1 and 2). For instance, Thapa and co-workers verified that the chemo-PTT mediated by folic acid-functionalized rGO co-loaded with irinotecan and docetaxel could reduce MCF-7 cells’ viability to about 24%.81 In stark contrast, the sole application of the dual drug loaded rGO based material (chemotherapeutic effect) or the conjugation of the rGO based material with NIR light (photothermal effect) only decreased cells’ viability to about 64 and 84%, respectively.81 In another work, Feng et al. verified that the delivery of doxorubicin (DOX) through PEGylated pH-responsive GO to DOX-resistant MCF-7 cells could reduce their viability to about 55% (Fig. 3).82 In turn, the chemo-photothermal effect mediated by the DOX loaded GFN reduced cells’ viability to about 21%,82 proving to be a promising agent for the elimination of drugresistant cancer cells.\nThe hyperthermia induced by GFN can also enhance nanostructures’ ability to deliver drugs to the tumor tissue. In this regard, Li et al. verified that the delivery of a platinum complex by PEGylated GO would result in a platinum tumor accumulation of 9.6 µg g−1 (Fig. 4).77 In contrast, mice treated with the platinum-PEG-GO complex plus NIR light presented a platinumTa b le 1 (C o n td .) G FN\nM od\nal it y\nTu m or\nm od\nel A dm\nin is tr at io n\nro ut e\nD os e\nLa se r pa ra m et er s\nTu m or te m pe\nra tu re\no\nO ut co m e of co m bi n at io n th er ap\ny O ut co m e of\nst an\ndal on e th er ap ie s\nR ef .\nPV Pn /B iP\n5 W\n3 0 -r G O\nR ad\nio -P T T\nH eL\na tu m or be ar in g m ic e\ni.t .\nPV P/ B iP\n5 W\n3 0 -r G O :\n40 µg\n80 8 n m ,0\n.3 5 W\ncm − 2 ,1\n0 m in\n45 °C\nTu m or er ad\nic at io n (i n\n1 ou\nt of\n4 m ic e)\nPV P/ B iP\n5 W\n3 0 -r G O +\nN IR :t um\nor gr ow th re du ct io n\n76\nX -r ay :6\nG y\nPV P/ B iP\n5 W\n3 0 -r G O +\nX -r ay :t um\nor gr ow th re du ct io n X -r ay :t um or gr ow th re du ct io n\nC pG\nO D N s co m pl ex ed PE IPE G -G O\nIm m un\noPT\nT C T 26\ntu m or be ar in g m ic e\ni.t .\nPE IPE\nG -G O :2\nm g\nkg − 1\n80 8 n m ,2 W cm − 2 ,5 m in\n50 °C\nTu m or re gr es si on\nPE IPE\nG -G O + N IR :\ntu m or\ngr ow\nth re du\nct io n\n79\nC pG\nO D N s: 18\n0 µg\nkg − 1\nC pG\nO D N s co m pl ex ed\nPE IPE\nG -G O :t um or gr ow th re du ct io n C pG O D N s: tu m or gr ow th re du ct io n\na In tr av en\nou s (i .v .).\nb E pi ru bi ci n (E PI ).\nc R es ve ra tr ol\n(R V ).\nd M et h ox yP\nE G (m\nPE G ).\ne In tr at um\nor al\n(i .t .).\nf M it ox an\ntr on\ne (M\nIT ).\ng H ya lu ro n ic\nac id\n(H A ).\nh 1, 2- D is te ar oy l-s ngl yc er o3- ph\nos ph\noe th an ola m in eN -P E G (D SP E -P E G ). i A sn -G ly -A rg pe pt id e (N G R ). j PE G di m et h yl et h er (P E G D E ). k B ra n ch ed PE I (b PE I) . l In tr ap er it on ea l (i .p .). m Po ly (m al ei c an h yd ri de -a lt -1 -o ct ad ec en e) (C 1 8 PM H ). n Po ly (v in yl py rr ol id on e) (P V P) .o T h e va lu e of th e tu m or ’s te m pe ra tu re is ap pr ox im at ed .N ot av ai la bl e (N .A .).\nBiomater. Sci. This journal is © The Royal Society of Chemistry 2019\nPu bl\nis he\nd on\n2 4\nJu ne\n2 01\n9. D\now nl\noa de\nd by\nK E\nA N\nU N\nIV E\nR SI\nT Y\no n\n7/ 18\n/2 01\n9 8:\n23 :3\n5 A\nM .\nT ab\nle 2\nC o m b in at io n P T T m e d ia te d b y G FN\n: in\nvi tr o re su\nlt s\nG FN\nM od\nal it y\nC el ll in e\nD os e\nLa se r pa\nra m et er s\nC el lv\nia bi li ty\naf te r co m bi n at io n th er ap\nyo C el lv\nia bi li ty\naf te r st an\ndal on\ne th er ap\nie so\nR ef .\nD O X lo ad\ned D SP\nE -P E G -N H\n2 /G O N R\nC h em\noPT\nT U 87\nce lls\nD O X :≈\n16 .6\nµg m L−\n1 80\n8 n m ,2\nW cm\n− 2 ,\n2 m in\n2% D O X lo ad\ned D SP\nE -P E G -N H\n2 /G O N R :3\n6% 96\nFr ee\nD O X :5 9% E PI lo ad ed C et ux im ab -P E G -G O C h em oPT T U 87 ce lls E PI :≈ 14 µg m L− 1 80 8 n m ,2 W cm − 2 , 2 m in 2% E PI lo ad\ned C et ux\nim ab\n-P E G -G O :1\n4% 64\nFr ee\nE PI :5 5% Pl at in um -P E G -G O co m pl ex C h em oPT T 4T 1 ce lls PE G -G O :8 90 µg m L− 1 78 5 n m ,1 .5 W cm − 2 , 3 m in 2% PE\nG -G O + N IR :8\n% 77\nPt :1\n00 µM\nPl at in um\n-P E G -G O co m pl ex :1 3% Fr ee Pt (II ): 24\n% M IT lo ad ed H A -G O C h em oPT T M C F7 ce lls M IT :5 1. 2 µg m L− 1 80 8 n m ,2 W cm − 2 , 3 m in 3% H A -G O + N IR :4\n0% 65\nM IT\nlo ad\ned H A -G O :1 4% Fr ee M IT :2\n3% D SP E -P E G -N G R /D O X -G O @ A g n an oc om po si te C h em oPT T M C F7 ce lls D O X :4 µg m L− 1 80 8 n m ,2 W cm − 2 , 3 m in 6% D SP\nE -P E G -N G R /D\nO X -G O @ A g\nn an\noc om\npo si te :3\n6% 85\nFr ee\nD O X :3 7% D O X lo ad ed la ct of er ri n /r G O ba se d n an oc ap su le s C h em oPT T R G 2 ce lls D O X :0 .2 5 µg m L− 1 80 8 n m ,2 W cm − 2 , 5 m in 6% La\nct of er ri n /r G O ba\nse d n an\noc ap\nsu le s +\nN IR :8\n4% 83\nD O X lo ad\ned la ct of er ri n /r G O ba\nse d\nn an\noc ap\nsu le s: 87 % Fr ee D O X :5\n1% T PG Sa /r G O C h em oPT T M C F7 ce lls rG O :1 0 µg m L− 1 80 8 n m ,1 .7 W cm − 2 , 5 m in 6% T PG S/ rG O :3\n7% 23\nSo ra fe n ib\nlo ad\ned PV\nP/ FA\nb -G O\nC h em\noPT\nT K B ce lls\nSo ra fe n ib :1\n00 µM\nN IR ,3\nW cm\n− 2 ,5\nm in\n7% PV\nP/ FA\n-G O + N IR :8\n2% 97\nSo ra fe n ib\nlo ad\ned PV\nP/ FA\n-G O :1 6% Fr ee So ra fe n ib :2\n6% T PG S/ G O C h em oPT T M C F7 ce lls G O :1 0 µg m L− 1 80 8 n m ,1 .7 W cm − 2 , 5 m in 8% T PG S/ G O :7\n5% 23\nD O X lo ad\ned PV\nP/ FA\n-G O\nC h em\noPT\nT H eL\na ce lls\nD O X :2\n0 µg\nm L−\n1 80\n8 n m ,2\nW cm\n− 2 ,\n5 m in\n10 %\nD O X lo ad\ned PV\nP/ FA\n-G O :2\n9% 98\nFr ee\nD O X :3 0% D O X lo ad ed m PE G -G O C h em oPT T E M T 6 ce lls D O X :3 0 µg m L− 1 80 8 n m ,2 W cm − 2 , 3 m in 10 % m PE\nG -G O + N IR :1\n7% 95\nFr ee\nD O X :2 1% D O X lo ad ed D A -P A H c - PE G -G O C h em oPT T M C F7/ A D R ce lls G O :≈ 40 µg m L− 1 80 8 n m ,0 .5 W cm − 2 , 5 m in 21 %\nD A -P A H -P E G -G O + N IR :7\n4% 82\nD O X :2\n0 µg\nm L−\n1 D O X lo ad\ned D A -P A H -P E G -G O :5 5% Fr ee D O X :8\n8% D O X lo ad ed PE G -b PE IrG O C h em oPT T H eL a ce lls D O X :5 0 µg m L− 1 80 8 n m ,6 W cm − 2 , 30 m in 22 % D O X lo ad ed PE\nG -b PE\nIrG\nO :5\n6% 53\nFr ee\nD O X :9 % D O X lo ad ed H A -S SG O C h em oPT T M D A -M B -2 31 D O X :5 µg m L− 1 80 8 n m ,5 W cm − 2 , 5 m in 22 %\nH A -S SG O + N IR :7\n3% 84\nD O X lo ad\ned H A -S SG O :3 3% IR Id an d D O C e lo ad ed FA -P 40 7 f / rG O C h em oPT T M C F7 ce lls IR I + D O C :1 00 µM N IR ,3 W cm − 2 ,5 m in 24 % FA -P 40 7/ rG O + N IR :8\n4% 81\nIR I an\nd D O C lo ad\ned FA\n-P 40\n7/ rG\nO :6 4% Fr ee IR I + D O C :7\n4% D O X an d IR I lo ad ed P1 88 g / G O C h em oPT T SC C -7 ce lls G O :≈ 6 µg m L− 1 80 8 n m ,3 W cm − 2 , 5 m in 35 % P1 88 /G O + N IR :6\n7% 99\nD O X + IR I: 1 µg\nm L−\n1 D O X an\nd IR I lo ad\ned P1\n88 /G O :6 6% Fr ee D O X + IR I: 64\n% D O X an d TO Sh lo ad ed C 1 8 PM H -P O xi /G O C h em oPT T M C F7 ce lls G O :3 4. 7 µg m L− 1 80 8 n m ,1 .7 W cm − 2 , 5 m in 39 % D O X an d TO S lo ad\ned C 1 8 PM\nH -P O x/ G O :\n61 %\n49\nD O X + TO\nS: 20\n.5 µM\nFr ee\nD O X + TO\nS: 74 % R V lo ad ed m PE G /r G O C h em oPT T 4T 1 ce lls G O :2 2 µg m L− 1 80 8 n m ,0 .6 W cm − 2 , 3 m in 55 % m PE G /r G O + N IR :9\n9% 54\nR V :4\n0 µg\nm L−\n1 R V lo ad\ned m PE\nG /r G O :6\n5%\nThis journal is © The Royal Society of Chemistry 2019 Biomater. Sci.\nPu bl\nis he\nd on\n2 4\nJu ne\n2 01\n9. D\now nl\noa de\nd by\nK E\nA N\nU N\nIV E\nR SI\nT Y\no n\n7/ 18\n/2 01\n9 8:\n23 :3\n5 A\nM .\nT ab\nle 2\n(C o n td .)\nG FN\nM od\nal it y\nC el ll in e\nD os e\nLa se r pa\nra m et er s\nC el lv\nia bi li ty\naf te r co m bi n at io n th er ap\nyo C el lv\nia bi li ty\naf te r st an\ndal on\ne th er ap\nie so\nR ef .\nR V lo ad\ned PE\nG D E /G O\nC h em\noPT\nT 4T\n1 ce lls\nR V :5\n0 µg\nm L−\n1 80\n8 n m ,0\n.6 W\ncm − 2 ,\n3 m in\n71 %\nR V lo ad\ned PE\nG D E /G O :8\n0% 54\nIR 80\n8- bP\nE IPE\nG -G O\nPh ot od\nyn am\nic -\nPT T\nLe w is\nce lls\nIR 80\n8: 10\nµM 80\n8 n m ,2\nW cm\n− 2 ,\n5 m in\n0% bP\nE IPE\nG -G O + N IR :7\n5% 66\nFr ee\nIR 80\n8 + N IR :3 8% C e6 lo ad ed PE G -G O Ph ot od yn am ic - PT T K B ce lls C e6 :2 .5 µM 80 8 n m ,0 .3 W cm − 2 , 20 m in 2% C e6 lo ad ed PE\nG -G O + N IR :8\n3% 40\n66 0 n m ,0\n.0 5 W\ncm − 2 ,\n5 m in\nC e6\nlo ad\ned PE\nG -G O + 66\n0 n m :2 5% Fr ee C e6 + 66 0 n m :1 00 %\nM et h yl en\ne bl ue\nlo ad\ned Pl ur on ic F1 27 /G O\nPh ot od\nyn am\nic -\nPT T\n4T 1 ce lls\nPl ur on\nic F1\n27 /G O :1\n2. 5 µg\nm L−\n1 66\n0 n m ,3\n4 J cm\n− 2 ,\n3 m in\n5% M et h yl en\ne bl ue\nlo ad\ned Pl ur on\nic F1\n27 /\nG O + 66\n0 n m :4\n% 89\nM et h yl en\ne bl ue\n:2 .5\nµg m L−\n1 80\n8 n m ,1\n.6 5 kJ\ncm − 2 ,\n3 m in\nPl ur on\nic F1\n27 /G O + N IR :6 6% Fr ee M B + 66 0 n m :4\n% PE G -R u( II )c om pl ex lo ad ed rG O Ph ot od yn am ic - PT T A 54 9 ce lls PE G -R u( II )c om pl ex :6 .2 5 µM 80 8 n m ,0 .5 W cm − 2 , 5 m in 8% PE G -R u( II )c om pl ex\nlo ad\ned rG\nO + N IR :\n18 %\n88\n45 0 n m ,2\n0 m W\ncm − 2 ,\n2 m in\nPE G -R u(\nII )c\nom pl ex\nlo ad\ned rG\nO +\n45 0 n m :5 2% Zn Pc j lo ad ed U C N Ps k - PE G -G O Ph ot od yn am ic - PT T H eL a ce lls Zn Pc lo ad ed U C N Ps -P E G -G O : 80 µg m L− 1 80 8 n m ,2 W cm − 2 , 10 m in 16 % Zn Pc lo ad\ned U C N Ps\n-P E G -G O + N IR :7\n4% 86\n63 0 n m ,5\n0 m W\ncm − 2 ,\n10 m in\nZn Pc\nlo ad\ned U C N Ps\n-P E G -G O + 63\n0 n m :\n50 %\nM et h yl en\ne bl ue\nlo ad\ned Pl ur on ic F1 27 /G O\nPh ot od\nyn am\nic -\nPT T\nH eL\na ce lls\nPl ur on\nic F1\n27 /G O :1\n0 µg\nm L−\n1 65\n5 n m ,≈\n15 0 m W\ncm − 2 ,3\nm in\n23 %\nPl ur on\nic F1\n27 /G O + N IR :4\n1% 87\nM et h yl en\ne bl ue\n:2 µg\nm L−\n1 80\n8 n m ,2\nW cm\n− 2 ,\n3 m in\nM et h yl en\ne bl ue\nlo ad\ned Pl ur on\nic F1\n27 /\nG O + 65\n5 n m :4 9% Fr ee M et h yl en\ne bl ue\n+ 65\n5 n m :5 7% C 6 0 l -m PE G -G O Ph ot od yn am ic - PT T H eL a ce lls G O :4 0 µg m L− 1 80 8 n m ,4 W cm − 2 , 7 m in 59 % m PE G -G O + N IR :7\n8% 10 0 C 6 1 (C O O N a) 2 :1 0. 4 µg m L− 1 Fr ee C 6 1 (C O O N a) 2 + N IR :8 1% 1 3 1 I la be le d C 1 8 PM H -P E G /r G O R ad io -P T T 4T 1 ce lls C 1 8 PM H -P E G /r G O :1 00 µg m L− 1 80 8 n m ,0 .5 W cm − 2 , 10 m in 6% C 1 8 PM H -P E G /r G O + N IR :8 7% 62 1 3 1 I: 10 0 µC im L− 1 1 3 1 I la be le d C 1 8 PM H -P E G /r G O :5 0% Fr ee 1 3 1 I: 89 % IU dR lo ad ed PL G A m /G O R ad io -P T T U 87 M G ce lls IU dR lo ad ed PL G A /G O :8 0 µg m L− 1 80 8 n m ,2 W cm − 2 , 3 m in ; 29 % n PL G A /G O + N IR :6 3% n 93 IU dR :0 .3 5 µg m L− 1 IU dR lo ad ed PL G A /G O + X -r ay :3 8% n X -r ay :2 G y Fr ee IU dR + X -r ay :5 5% n a D -α -T oc op h er ol po ly et h yl en e gl yc ol 10 00 su cc in at e (T PG S) . b Fo li c ac id (F A ). c 2, 3- D im et h yl m al ei c an h yd ri de m od if ie d PA H (D A -P A H ). d Ir in ot ec an (I R I) . e D oc et ax el (D O C ). f Po lo xa m er 40 7 (P 40 7) .g Po lo xa m er 40 7 (P 18 8) .h D -α -T oc op h er ol su cc in at e (T O S) .i Po ly (2 -e th yl -2 -o xa zo li n e) (P O x) .j Zi n c ph th al oc ya n in e (Z n Pc ). k U pc on ve rs io n n an op ar ti cl es (U C N P) .l Fu lle re n e (C 6 0 ). m Po ly (l ac ti de -c ogl yc ol id e) (P LG A ). n Pl at in g effi ci en cy .o T h e va lu es of th e ce lls ’ vi ab il it y ar e ap pr ox im at ed .\nBiomater. Sci. This journal is © The Royal Society of Chemistry 2019\nPu bl\nis he\nd on\n2 4\nJu ne\n2 01\n9. D\now nl\noa de\nd by\nK E\nA N\nU N\nIV E\nR SI\nT Y\no n\n7/ 18\n/2 01\n9 8:\n23 :3\n5 A\nM .\ntumor uptake of 13.3 µg g−1.77 As a result, the chemo-PTT mediated by platinum-PEG-GO complex induced tumors’ eradication while the sole application of chemotherapy (platinum or platinum-PEG-GO complex) or PTT (PEG-GO + NIR) only led to a reduction or inhibition of the tumors’ growth, respectively.77 A similar observation was reported by Shi et al., which verified that the DOX released in the tumor tissue of mice treated with a DOX-GO based conjugate could be increased by about 1.65 times upon NIR laser irradiation.85"
    }, {
      "heading" : "5. PTT mediated by GFN in combination with photodynamic therapy",
      "text" : "GFN aromatic structure can incorporate photosensitizers for application in combination photodynamic-PTT. For this purpose, chlorin e6 (Ce6) and phthalocyanine derivatives have been adsorbed on GFN surface by taking advantage from hydro-\nphobic–hydrophobic interactions and/or π–π stacking.40,86 Furthermore, photosensitizers may also be included on GFN through electrostatic interactions or covalent bonding.66,87\nIdeally, the photosensitizers incorporated on GFN should have a high absorption in the NIR region, allowing the NIR radiation to excite both the photodynamic agent and the GFN (photothermal agent).66 However, most of the photosensitizers incorporated so far on GFN do not have a high NIR absorption.40,87–89 In this way, the combination photodynamic-PTT mediated by GFN commonly employs radiation with a wavelength suitable for the photosensitizer (e.g. 660 nm radiation for Ce6) and 808 nm radiation for the GFN40 (Tables 1 and 2). The photoinduced heat generated by GFN can induce the release of the loaded photosensitizers from GFN structure.88 This phenomenon has a great importance since GFN can quench the reactive oxygen species (e.g. singlet oxygen) generated by the photosensitizers upon irradiation.86–88 In this way, the NIR light induced release of the photodynamic agents, from the structure of GFN, can potentially restore their activity.\nFig. 3 Properties of DOX loaded PEG functionalized pH-responsive GO. (a) Optical and infrared thermal images of water and PEG functionalized pH-responsive GO upon exposure to NIR light (808 nm, 1 W cm−2, 5 min). (b) Temperature variation curves of PEG functionalized pH-responsive GO upon NIR laser irradiation. (c) Chemo-PTT effect mediated by DOX loaded PEG functionalized pH-responsive GO towards DOX-resistant MCF-7 cells (808 nm, 0.5 W cm−2, 5 min; with laser irradiation). DOX loaded PEG functionalized pH-responsive GO (NGO-PEG-DA/DOX), PEG functionalized pH-responsive GO (NGO-PEG-DA). Copyright © 2014 by John Wiley & Sons, Inc. Reprinted from ref. 82 by permission of John Wiley & Sons, Inc.\nThis journal is © The Royal Society of Chemistry 2019 Biomater. Sci.\nPu bl\nis he\nd on\n2 4\nJu ne\n2 01\n9. D\now nl\noa de\nd by\nK E\nA N\nU N\nIV E\nR SI\nT Y\no n\n7/ 18\n/2 01\n9 8:\n23 :3\n5 A\nM .\nMoreover, the temperature increase induced by GFN upon NIR laser irradiation can improve the uptake of these nanomaterials by cells.40 In this regard, Tian et al. observed that the intracellular delivery of Ce6 by PEGylated GO is improved by 2–3 fold upon NIR laser irradiation.40\nIn this way, the combination photodynamic-PTT mediated by GFN can result in an enhanced therapeutic outcome (Tables 1 and 2). Dos Santos et al. verified that the irradiation of Pluronic F127 functionalized GO incorporating methylene blue with 660 and 808 nm lights generates a combined photodynamic–photothermal effect capable of ablating mice tumors and of preventing metastasis in major organs.89 In contrast, the sole application of the photodynamic (methylene blue loaded GO based material + 660 nm radiation) and photothermal (methylene blue loaded GO based material + 808 nm radiation) treatments only induced a slight reduction in the tumor’s growth and did not inhibit the occurrence of metastases.89 In another work, the combined photodynamic-PTT mediated by rGO incorporating a PEGylated Ru(II) complex (photosensitizer) also induced a superior therapeutic outcome when compared to the sole application of PTT (PEG-Ru(II)/rGO plus 808 nm radiation) or photodynamic therapy (PEG-Ru(II)/ rGO plus 450 nm radiation).88"
    }, {
      "heading" : "6. PTT mediated by GFN in combination with gene therapy",
      "text" : "GFN can be modified with polycations to enable their application in gene delivery. In this regard, GFN functionalized with poly(ethylenimine) (PEI), poly(allylamine hydrochloride) (PAH) and chitosan can form complexes with pDNA or siRNA through electrostatic interactions established between the polycations and the negatively charged groups of the genetic material.72,90,91\nThe photoinduced heat generated by GFN can further enhance their gene delivery capabilities.72,80 In fact, the transfection efficiency mediated by GFN can be augmented by increasing cells’ exposure to the NIR light.80 For instance, Feng et al. verified that the PEI-PEG-GO mediated transfection of cancer cells with EGFP can be increased by up to ≈10 times upon NIR laser irradiation.72 In other work, the photothermal transfection efficiency of PEG-PEI-rGO was also 2–3 times greater than that attained without the use of NIR light.80 Furthermore, the conjugation of NIR light and GFN incorporating siRNA can also result in an improved gene silencing (Fig. 5).72\nThe photothermally enhanced gene transfection/silencing mediated by GFN can be explained by the improved uptake of\nFig. 4 In vivo outcome of the chemo-PTT mediated by platinum-PEG-GO complex. (A) Relative tumor volume changes of mice exposed to different treatments. Photos of the tumors (B) and mice (C) at the end point of the study. (D) Pt content in mice’s major organs and tumor. (E) Hematoxylin and eosin staining of the mice’s tumor tissue. Cisplatin (Pt(II)), NIR light irradiation (785 nm, 1.5 W cm−2, 3 min; +NIR), Non-irradiated (-NIR), PEG-GO (PEG-NGO), Phosphate Buffered Saline (PBS), Platinum-PEG-GO complex (PEG-NGO-Pt). Reprinted from ref. 77, Copyright (2015), with permission from Elsevier.\nBiomater. Sci. This journal is © The Royal Society of Chemistry 2019\nPu bl\nis he\nd on\n2 4\nJu ne\n2 01\n9. D\now nl\noa de\nd by\nK E\nA N\nU N\nIV E\nR SI\nT Y\no n\n7/ 18\n/2 01\n9 8:\n23 :3\n5 A\nM .\nthese nanomaterials by cells achieved after NIR laser irradiation.72 Moreover, the photoinduced heat generated by both GO and rGO based materials can also induce the escape of these materials from the endosomes, further contributing to their improved gene transfection capabilities.80,92 Importantly, both of these two phenomena appear to be mediated by the site-specific temperature increase mediated by GFN upon exposure to NIR light, since the direct heating of the cells at 43 °C did not result in an enhanced cellular uptake/improved endosomal escape.72,80 In this way, the combination of the gene delivery and PTT mediated by GFN can result in an improved therapeutic outcome (Table 1). Yin et al. studied the therapeutic capacity of PAH/Folic acid-PEG-GO complexed with siRNA targeting the HDAC1 and K-Ras genes.90 When compared to mice treated with saline (control), the combined effect of the GO based material and NIR light (PTT) was able to reduce mice tumor’s weight by ≈38%.90 On the other hand, the siRNA-GO based complex (gene delivery) induced a tumor weight reduction of ≈78%.90 In stark contrast, the combination of the siRNA-GO based complex with NIR light reduced mice tumor’s weight by ≈95%,90 thereby confirming the superior efficacy of the GFN photothermally enhanced gene delivery."
    }, {
      "heading" : "7. PTT mediated by GFN in combination with radiotherapy",
      "text" : "The combination of GFN mediated PTT with radiotherapy is an emergent but promising approach. For this type of application, radionuclides can be labeled onto GFN, enabling internal radiotherapy.62 In this regard, Chen et al. labelled PEGylated rGO with 131I using the chloramine-T oxidation method.62 On the other hand, radiosensitizers such as 5-iodo-2′-deoxyuridine (IUdR) or bismuth heteropolytungstate (BiP5W30) can also be incorporated on GFN.\n76,93 These high-Z structures have an X-ray dose enhancement effect on cells, leading to an improved external radiotherapy.94\nThe temperature variation induced by GFN upon NIR irradiation can trigger the release of the loaded radiosensitizers.93 For instance, such phenomenon takes an important role for IUdR since this thymidine analog is incorporated on DNA.93 Moreover, GFN photoinduced heat can improve tumors’ oxygenation,76 sensitizing cancer cells to radiationinduced damage.\nIn this way, the application of GFN mediated radio-PTT can lead to improved therapeutic outcomes (Tables 1 and 2). Zhou and co-workers verified that poly(vinyl pyrrolidone)/BiP5W30rGO hybrids in combination with NIR light plus X-rays could induce a tumor growth inhibition ratio of ≈98%.76 In contrast, the effect of the hybrids plus NIR light or the hybrids plus X-rays only prompted tumor growth inhibition ratios of about 66 and 81%, respectively.76 The sole application of the X-rays only led to a ≈39% inhibition ratio.76 In another work, Chen et al. reported that the radio-PTT mediated by 131I labeled PEGylated rGO could induce tumor’s ablation in 4 out of 5 mice (Fig. 6).62 On the other hand, GFN mediated internal radiotherapy (131I-PEG-rGO) and GFN mediated PTT (PEG-rGO + NIR) only induced a reduction of the tumors’ growth.62"
    }, {
      "heading" : "8. PTT mediated by GFN in combination with immunotherapy",
      "text" : "Combining GFN mediated PTT with immunotherapy holds a great potential for cancer treatment. This pioneering approach\nFig. 5 Improved uptake and gene silencing mediated by PEI-PEG-GO under NIR laser irradiation. (a) Photothermally enhanced uptake of PEI-PEG-GO complexed with 6-carboxyfluorescein labelled siRNA by MDA-MB-435s cells. Plk1 mRNA (b) and protein (c) levels after treatment with PEI-PEG-GO complexed with Plk1 siRNA plus NIR light. Lipofectamine 2000 incorporating siPlk1 (Lipo-siPlk1), NIR light irradiation (808 nm, 0.5 W cm−2, 20 min; with irradiation), PEI-PEG-GO (NGO-PEG-PEI), siRNA targeting Plk1 (siPlk1), siRNA containing a scramble sequence (siN.C.). Copyright © 2013 by John Wiley & Sons, Inc. Reprinted from ref. 72 by permission of John Wiley & Sons, Inc.\nThis journal is © The Royal Society of Chemistry 2019 Biomater. Sci.\nPu bl\nis he\nd on\n2 4\nJu ne\n2 01\n9. D\now nl\noa de\nd by\nK E\nA N\nU N\nIV E\nR SI\nT Y\no n\n7/ 18\n/2 01\n9 8:\n23 :3\n5 A\nM .\nFig. 6 In vivo outcome of the radio-PTT mediated by 131I labeled PEGylated rGO. (a) Infrared thermal images of mice treated with 131I labeled PEGylated rGO in conjugation with NIR light irradiation. (b) Relative tumor volume changes of mice exposed to different treatments and (c) respective photos of the tumors at the end point of the study. (d) Tunnel staining of the mice’s tumor tissue. 131I labeled PEGylated rGO (131I-RGO-PEG), NIR light irradiation (808 nm, 0.2 W cm−2, 20 min; +laser), PBS (Control), PEGylated rGO (RGO-PEG). Reprinted from ref. 62, Copyright (2015), with permission from Elsevier.\nFig. 7 In vivo outcome of the immuno-PTT mediated by CpG ODNs/PEI-PEG-GO nanocomplex. (a) Schematic representation of the combination immuno-PTT. (b) Infrared thermal images of mice treated CpG ODNs/PEI-PEG-GO nanocomplex plus NIR light irradiation. (c) Relative tumor volume and body weight (d) changes of mice exposed to different treatments. Hematoxylin and eosin staining of the mice’s major organs after treatment with (e) PBS plus NIR radiation, (f ) PEI-PEG-GO, (g) CpG ODNs, (h) CpG ODNs/PEI-PEG-GO, (i) PEI-PEG-GO plus NIR radiation and ( j) CpG ODNs/ PEI-PEG-GO plus NIR radiation. CpG ODNs (CpG), CpG ODNs/PEI-PEG-GO nanocomplex (GO-PEG-PEI-CpG), NIR radiation (808 nm, 2 W cm−2, 5 min; +NIR), PEI-PEG-GO (GO-PEG-PEI). Reprinted from ref. 79, Copyright (2014), with permission from Elsevier.\nBiomater. Sci. This journal is © The Royal Society of Chemistry 2019\nPu bl\nis he\nd on\n2 4\nJu ne\n2 01\n9. D\now nl\noa de\nd by\nK E\nA N\nU N\nIV E\nR SI\nT Y\no n\n7/ 18\n/2 01\n9 8:\n23 :3\n5 A\nM .\nwas reported by Tao and co-workers which incorporated unmethylated cytosine-phosphate-guanine oligodeoxynucleotides (immunostimulatory molecules; CpG ODNs) on PEI-PEG-GO through electrostatic interactions.79\nThe authors verified that the uptake of the CpG ODNs/ PEI-PEG-GO complex by macrophages cells could be increased upon NIR laser irradiation.79 Moreover, the combination of the CpG ODNs/GFN nanocomplex with NIR light augmented macrophages’ TNF-α and IL-6 secretions by about 2.2- and 1.8- fold, respectively.79 Such enhanced immunogenicity is likely to result from the photothermally enhanced cellular uptake of the nanocomplex.79 In vivo, mice treated with the GFN mediated PTT (PEI-PEG-GO + NIR light) or with the GFN mediated immunotherapy (CpG ODNs/PEI-PEG-GO nanocomplex) just presented a ≈50 or 38% inhibition of the tumor’s growth, respectively (Fig. 7).79 In turn, the tumors of mice treated with the CpG ODNs/PEI-PEG-GO nanocomplex plus NIR radiation displayed a 91% growth inhibition, corroborating the improved therapeutic outcome arising from GFN mediated immuno-PTT.79"
    }, {
      "heading" : "9. Conclusion and outlook",
      "text" : "The combination of GFN mediated PTT with other therapeutic modalities has been showing promising results in cancer treatment. Among the different GFN, GO and rGO based materials have been the most explored for this therapeutic approach. The wide application of GO and rGO in combination PTT could be explained by their simpler synthesis when compared to the other GFN. On the other hand, the enhanced photothermal potential displayed by rGONR and rGONM should motivate their investigation in combination PTT.\nFurthermore, the analysis of the mechanisms involved in GFN mediated combination PTT revealed that the improved\noutcome arising from this therapeutic modality seems to be mainly related to the (i) photothermally enhanced cellular uptake, (ii) photothermally triggered compound release/endosomal-escape, and (iii) combined effect of the hyperthermia per se with the other therapies.\nAmong the different combination approaches, the conjugation of GFN mediated PTT with chemo- and photodynamictherapies was by far the most explored by researchers (Fig. 8). Such could be related to the fact that as-synthesized GFN can directly incorporate chemotherapeutics/photosensitizers on their structure through hydrophobic–hydrophobic interactions and/or π–π stacking. Moreover, some reports also revealed that GFN mediated chemo-PTT and photodynamic-PTT were able to induce the complete eradication of mice’s tumor, disclosing their high therapeutic efficacy (Fig. 8).\nRegarding the combination of GFN mediated PTT with gene-, radio- and immuno-therapies, the few studies on these modalities revealed promising results. Nevertheless, the therapeutic capacity of these emergent combination strategies is yet insufficiently explored, and thus should be further investigated.\nOverall, GFN mediated PTT holds a great potential for improving the efficacy of different types of therapies, which should motivate their continuous application for cancer treatment and investigation in the context of other diseases.\nConflicts of interest\nThe authors have no conflict of interest to declare."
    }, {
      "heading" : "Acknowledgements",
      "text" : "This work was supported by FEDER funds through the POCI – COMPETE 2020 – Operational Programme Competitiveness\nFig. 8 Frequency distribution of GFN mediated cancer combination PTT.\nThis journal is © The Royal Society of Chemistry 2019 Biomater. Sci.\nPu bl\nis he\nd on\n2 4\nJu ne\n2 01\n9. D\now nl\noa de\nd by\nK E\nA N\nU N\nIV E\nR SI\nT Y\no n\n7/ 18\n/2 01\n9 8:\n23 :3\n5 A\nM .\nand Internationalization in Axis I – Strengthening research, technological development and innovation (Project POCI-010145-FEDER-007491) and National Funds by FCT – Foundation for Science and Technology (Project UID/Multi/00709/2013). The funding from CENTRO-01-0145-FEDER-028989 is also acknowledged. Duarte de Melo-Diogo acknowledges CENTRO-01-0145FEDER-028989 for the funding given on the form of a research contract. Rita Lima-Sousa and Cátia G. Alves acknowledge funding from the grant UBI-Santander/Totta."
    } ],
    "references" : [ ],
    "referenceMentions" : [ ],
    "year" : 2019,
    "abstractText" : "Combining hyperthermia with other therapies holds a great potential for improving cancer treatment. In this approach, the increase in the body temperature can exert a therapeutic effect on cells and/or enhance the effectiveness of anticancer agents. However, the conventional methodologies available to induce hyperthermia cannot confine a high temperature increase to the tumor-site while maintaining healthy tissues unexposed and ensuring minimal invasiveness. To overcome these limitations, combination photothermal therapy (PTT) mediated by graphene family nanomaterials (GFN) has been showing promising results. Such is owed to the ability of GFN to accumulate at the tumor site and convert near infrared light into heat, enabling a hyperthermia with a high spatial-temporal resolution. Furthermore, GFN can also incorporate different therapeutic agents on their structure for delivery purposes to cancer cells. In this way, the combination PTT mediated by GFN can result in an improved therapeutic effect. In this review, the combination of GFN mediated PTT with chemo-, photodynamic-, gene-, radio-, and immuno-therapies is examined. Furthermore, the main parameters that influence these types of combination approaches are also analyzed, with emphasis on the photothermal potential of GFN and on the vascular and cellular effects produced by the temperature increase mediated by GFN.",
    "creator" : "Arbortext Advanced Print Publisher 9.1.520/W Unicode"
  }
}